Is SLL better than CLL?

The difference between SLL and CLL is where the blood cancer is located. CLL has most of the cancerous B lymphocytes in the bloodstream (like a leukaemia), whereas SLL has most of the cancerous B lymphocytes in the lymph nodes and lymphoid tissue such as the spleen and the tonsils (like a lymphoma).

Can you have CLL and SLL?

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma When the cancer cells are located mostly in the lymph nodes, the disease is called SLL. Many patients with CLL/SLL do not have any obvious symptoms of the disease.

Is SLL same as CLL?

CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are the same disease, but in CLL cancer cells are found mostly in the blood and bone marrow. In SLL cancer cells are found mostly in the lymph nodes. CLL/SLL is a type of non-Hodgkin lymphoma.

Is CLL a form of lymphoma?

Chronic lymphocytic leukemia/small lymphocytic lymphoma is a type of non-Hodgkin lymphoma.

What percentage of CLL patients need treatment?

It is important to emphasise that for many people CLL remains stable for many months and years and has little, if any, impact on their lifestyle or general health. Around 30-50% of people diagnosed with CLL never require any treatment for their disease and can survive for many years despite their diagnosis.

Is there a Phase 3 trial for ibrutinib?

The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relapsed patients with CLL, provided support for approval of ibrutinib in the United States and Europe.

Is there a cure for CLL with ibrutinib?

Blood (2019) 133 (19): 2031–2042. A related article has been published: Ibrutinib: the home run for cure in CLL?

Are there long term safety signals for ibrutinib?

Overall survival outcomes were sustained and no long-term safety signals have emerged with 4 years of follow-up on ibrutinib treatment. Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL).

What are the covariates for PFS in ibrutinib?

Multivariate analysis for PFS in the ibrutinib arm was conducted with the following potential covariates included in the model: age, Rai stage, Eastern Cooperative Oncology Group (ECOG) status, number of prior lines of therapy, del (17) (p13.1) status, del (11) (q22.3) status, B2M, lactate dehydrogenase, and refractory status to purine analogs.